| Product Name |
Anti-IL-13RA2 monoclonal
antibody, recombinant |
| Cat # |
EG-373 |
| Size |
100 µg |
| Key features |
Rabbit monoclonal antibody
produced in 293 cells with serum-free, protein-free medium, purified
with protein A column;
High batch-to-batch consistency and reproducibility;
Long term security of supply; |
| Clone number |
M2 |
| Immunogen |
Recombinant extracellular
domain of interleukin 13 receptor alpha 2 (IL-13RA2) that was expressed
and purified from 293 cells |
| Reaction
target |
Extracellular region of
IL-13RA2 |
| Species
Cross-Reactivity |
Human |
| Applications |
Flow Cytometry; IP; ELISA; |
| Working
concentrations |
Flow cytometry and ELISA: 5
µg/ml of final concentration is suggested.
IP: 10 µg in 0.3-0.5 mg cell lysates is suggested.
|
| Background |
The interleukin-13 receptor
alpha 2 (IL-13RA2)
is a high-affinity membrane receptor for interleukin-13 (IL-13). IL-13
is a T helper 2（Th2）cell-derived pleiotropic immune regulatory cytokine
that binds available IL-13RA2 with 50-fold higher affinity than the
ubiquitously expressed receptor named interleukin-13 receptor alpha 1
(IL-13RA1) [1]. Under normal physiological conditions, IL-13 binds to
the low-affinity receptor IL-13RA1 monomer and further forms a
heterodimeric complex with IL-4RA, which subsequently triggers Janus
kinase and signal transducer activation and activator of transcription
(STAT). However, in cancer cells, IL-13 can bind IL-13Rα2 with high
affinity in an IL-4-independent manner. IL-13RA2 is over-expressed in a
vast majority of human patients with high-grade astrocytomas like
glioblastoma, but not in normal brain tissues. Therefore, IL-13RA2 is a
potential target for immunotherapy of glioblastoma, which is one of the
most lethal brain tumors and there are no curative treatment modalities
for this type of cancer. IL-13 fused pseudomonas exotoxin has been
evaluated for its anti-tumor efficacy in clinical trials by targeting
IL-13RA2, but failed due to side effect.
References:
(1) Arima, K., et al., Characterization of the interaction between
interleukin-13 and interleukin-13 receptors. J Biol Chem, 2005; 280:
24915-22.
|
| QC |
ELISA assay showing protein binding affinity of the
monoclonal antibody. The calculated EC50 value was 0.05 nM.
|
| Concentration |
As indicated on the vials |
| Formulation |
80% PBS, pH 7.4; 20%
Glycerol; 5% Trehalose; 0.04% Sodium azide as Preservative |
| Shipping |
Blue ice |
| Storage |
-20 to -70 oC
(long term)
or 4 oC (one week).
Depending on the expected application frequency, the product can be
aliquoted to avoid heavily repeated freezing/thawing cycles. |